The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

Metabolism: Clinical and Experimental

Volumn 51, Issue 5, 2002, Pages 636-641

  Fineman, M S ^a   Koda, J E ^a   Shen, L Z ^a   Strobel, S A ^a   Maggs, D G ^a   Weyer, C ^a   Kolterman, O G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; GLUCAGON; GLUCOSE; INSULIN; PLACEBO; PRAMLINTIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; FOOD DRUG INTERACTION; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLUCAGONEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MEAL; PARALLEL DESIGN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE;

EID: 0036257258     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.32022     Document Type: Article

References (33)

1. Co-secretion of amylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents
2. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans
3. Neuroendocrine actions of amylin
4. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control
5. Amylin concentrations and glucose control
6. Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks
7. Pramlintide therapy in addition to insulin in type 1 diabetes: Effect on metabolic control after 6 months
8. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
9. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
10. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin
11. Relationships of upper gastrointestinal motor and sensory function with glycemic control
12. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas
13. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus
14. Studies of pancreatic alpha cell function in normal and diabetic subjects
15. Types of diabetes according to National Diabetes Data Group classification - Limited applicability and need to revisit
16. A comparative study of hexokinase from yeast and animal tissues
17. Effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM
18. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus
19. Interplay of nutrients and hormones in the regulation of glucagon release
20. Interrelationship of glucagon, insulin, and glucose. The insulinogenic effect of glucagon
21. Correction of hyperglycemia with phlorizin restores the glucagon response to glucose in insulin-deficient dogs: Implications for human diabetes
22. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics
23. The effect of experimental insulin deficiency on glucagon secretion
24. Dose-response for glucagonostatic effect of amylin in rats
25. Amylin's physiology and its role in diabetes
26. The role of amylin in the physiology of glycemic control
27. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion
28. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus
29. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats
30. In type 1 diabetes, addition of pramlintide to insulin therapy resulted in long-term glycemic improvement without the increase in severe hypoglycemia noted in patients treated with insulin alone
31. In vitro autoradiographic localization of amylin binding sites in rat brain
32. Area postrema (AP)-lesions block the regulation of gastric emptying by amylin
33. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve